CITRANVI RATIONALLY ENGINEERED CARRIER PROTEINS
We are developing innovative research tools and Systems for Immunogenicity Enhancement, with particular reference to multicomponent bacterial and viral vaccines. Citranvi's proprietary Rationally Engineered Carrier Proteins (reCaP) platform is geared towards incorporation of antigens from a broad variety of pathogens to produce Self-Assembling Adjuvanted Nanoparticles (SAANPs). When reCaPs are chemically conjugated or genetically fused to poor immunogens, the ability to elicit serum as well as secretory antibodies against the fused antigens could be enhanced. The integrated design feature of SAANPs is to act as trans-mucosal carrier delivery systems when covalently linked to antigens. These design features are particularly applicable for vaccine antigens to target pandemic viral pathogens, such as coronaviruses to generate mucosal immune responses.
We are developing innovative research tools and Systems for Immunogenicity Enhancement, with particular reference to multicomponent bacterial and viral vaccines. Citranvi's proprietary Rationally Engineered Carrier Proteins (reCaP) platform is geared towards incorporation of antigens from a broad variety of pathogens to produce Self-Assembling Adjuvanted Nanoparticles (SAANPs). When reCaPs are chemically conjugated or genetically fused to poor immunogens, the ability to elicit serum as well as secretory antibodies against the fused antigens could be enhanced. The integrated design feature of SAANPs is to act as trans-mucosal carrier delivery systems when covalently linked to antigens. These design features are particularly applicable for vaccine antigens to target pandemic viral pathogens, such as coronaviruses to generate mucosal immune responses.
We are developing scalable and commercially viable platforms and processes for end-to-end Vaccine Development, with particular reference to Conjugate Vaccine Development and Bioconjugation, including Nanoparticles. The aim of the Citranvi platforms is to produce cost-effective vaccines by reducing the number of unit operations during manufacturing.